San Francisco, CA, September 30, 2021 – FlemingMartin is pleased to announce that Nurix Therapeutics (NASDAQ: NRIX), a company focused on discovering, developing, and commercializing first-in-class therapies for patients without adequate treatment options, has hired Michael Blackton as Senior Vice President of Cell Therapy Manufacturing.
Michael comes to Nurix after 6+ years at Adaptimmune (NASDAQ: ADAP), where he formulated the initial strategy for quality and manufacturing at the company and shaped the design of the CMC organization – Manufacturing, MS&T, Supply Chain Planning, and Quality. As the company grew and clinical trials progressed, Michael focused on leading the Quality Organization as VP of Global Quality reporting to the Chief Operating Officer.
Prior to joining Adaptimmune, Michael spent 11 years with Eli Lilly and Company and ImClone (acquired by Lilly in 2008), consistently being promoted to positions of increasing responsibility. This included the title of Associate Vice President of Validation Technical Services, where he was responsible for qualification, cleaning validation, multi-product strategies, regulatory documentation, and technology transfer initiatives and supported a broad portfolio of products, including CYRAMZA® (ramucirumab). Prior to joining Lilly, Michael served in various quality management roles at Millennium Pharmaceuticals (NASDAQ: MLNM) and Inhale Therapeutics (now Nektar Therapeutics, NASDAQ: NKTR).
Michael earned his MBA from New York University and he received his undergraduate degree in Biochemistry and Cell Biology from the University of California, San Diego.
Nurix is committed to bringing novel, first-in-class therapies to patients without adequate treatment options. Since its incorporation, Nurix has built a seasoned team of leaders with wide-ranging backgrounds in both small molecule drug development and adoptive cell therapy. Through its leadership in Targeted Protein Degradation and its powerful proprietary DELigase platform, Nurix has attracted world leading partners including its current drug discovery collaborations with Sanofi and Gilead Sciences. To learn more, visit www.nurixtx.com.
FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms, and CEOs of companies to build successful, execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital. www.flemingmartin.com